000			02289nam a2200481 i 4500
999			_c283544 _d283544
001			on1107052444
003			OCoLC
005			20190816144455.0
006			m o d f
007			cr |||||||||||
008			190702s2019 dcu o f000 0 eng c
024	8		_a36-619
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1016-C (online)
086	0		_aY 4.OV 2:116-07
088			_aSerial no. 116-07 (United States. Congress. House. Committee on Oversight and Reform)
099			_aY 4.OV 2:116-07
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Oversight and Reform,
245	1	0	_aTrump administration's response to the drug crisis : _bhearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, March 7, 2019.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2019.
300			_a1 online resource (iii, 68 pages)
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
500			_a"Serial no. 116-07."
500			_aAccess ID (govinfo): CHRG-116hhrg36619.
500			_aCRDP Program record.
511	0		_aHearing witnesses: James W. Carroll, Jr., Office of National Drug Control Policy; Triana McNeil, Acting Director, Strategic Issues, Government Accountability Office; Mike McDaniel, Director, Houston High Intensity Drug Trafficking Area.
518			_aDate of hearing: 2019-03-07.
588			_aDescription based on online resource; title from PDF title page (govinfo, viewed July 2, 2019).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Oversight and Reform. _tTrump administration's response to the drug crisis _w(OCoLC)1107265485
856	4	0	_3PDF version _uhttps://purl.fdlp.gov/GPO/gpo122680
856	4	0	_3Text version _uhttps://purl.fdlp.gov/GPO/gpo122681
050		4	_aKF27 _b.O96 2019e
610	1	0	_aUnited States. _bOffice of National Drug Control Policy _xCustomer services.
650		0	_aDrug control _zUnited States.
650		0	_aOpioid abuse _zUnited States.
650		0	_aOpioids _xOverdose _zUnited States _xPrevention.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8